Paediatric drug development

Nature Reviews Drug Discovery

Volumn 6, Issue 6, 2007, Pages 429-430

  Schachter, Asher D ^a   Ramoni, Marco F ^a,b  

^a HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^b LABORATORY FOR MOLECULAR MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

ARTICLE; CHILD SAFETY; CLINICAL RESEARCH; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG LEGISLATION; DRUG RESEARCH; DRUG SAFETY; HUMAN; OFF LABEL DRUG USE; PATENT; PRIORITY JOURNAL; RESEARCH SUBJECT; UNITED STATES;

CHILD; CLINICAL TRIALS; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; DRUG LABELING; HUMANS; LEGISLATION, DRUG; PEDIATRICS;

EID: 34447525059     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2333     Document Type: Article

References (10)

1. Kaushal, R. et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 285, 2114-2120 (2001).
2. Turner, S., Nunn, A. J., Fielding, K. & Choonara, I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: A prospective study. Acta Paediatr. 88, 965-968 (1999).
3. Neubert, A. et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf. 27 1059-1067 (2004).
4. Horen, B., Montastruc, J. L. & Lapeyre-Mestre, M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br. J. Clin. Pharmacol. 54, 665-670 (2002).
5. Gorman, R. L. Testimony of Richard L. Gorman, MD, FAAP on behalf of the American Academy of Pediatrics before the Committee on Health, Education, Labor and Pensions. US Senate Committee on Health, Education, Labor and Pensions web site [online], >http://help.senate.gov/Hearings/2007_03_27_b/Gorman.pdf> (2007).
6. Milne, C. & Faden, C. Pediatric study costs increased 8-fold since 2000 as complexity level grew. Tufts Center for the Study of Drug Developmnet Impact Report 9, (2007).
7. Li, J. S. et al. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA 297, 480-488 (2007).
8. Slikker, W. Jr. et al. Improving predictive modeling in pediatric drug development: Pharmacokinetics, pharmacodynamics, and mechanistic modeling. Ann. N. Y. Acad. Sci. 1053, 505-518 (2005).
9. Schachter, A. D. & Ramoni, M. F. Clinical forecasting in drug development. Nature Rev. Drug Discov. 6, 107-108 (2007).
10. Schreiner, M. S. Paediatric clinical trials: Redressing the imbalance. Nature Rev. Drug Discov. 2, 949-961 (2003).